Aqilion project company Trophea to be liquidated

Today AQILION AB announced that the extraordinary general meeting of the project company Trophea AB, with its wholly owned subsidiary Trophea Development AB, resolved to liquidate the companies. According to the decision, liquidation will begin on December 28, 2019.

Aqilion presents Nomination Committee for the 2020 Annual General Meeting

The Nomination Committee has been appointed and comprises the following members:
Helena Arcombe, appointed by the shareholder Länsförsäkringar
Malin Ruijsenaars, appointed by the shareholders Grenspecialisten AB and LMK Forward AB
Clas Runnberg, appointed to represent other shareholders
Lena Mårtensson, appointed to represent Aqilion’s network of advisors

Aqilion sells shareholdings in portfolio company Glactone Pharma

AQILION AB is selling its entire stake in the portfolio company Glactone Pharma AB to Daniel Lifveredson Invest AB. The purchase price is divided into a smaller amount as initial payment at the time of takeover and an additional payment based on Glactone Pharma’s future performance.

Aqilion project company Adenovir Pharma liquidated

Today AQILION AB announced that the extraordinary general meeting of the project company Adenovir Pharma AB resolved to liquidate the company. According to the decision, liquidation will begin on…

Aqilion initiates collaboration with Immunscape

Aqilion searches for early innovative pharmaceutical projects thatare based on solid research resting on a firm biological foundation and offering both clinical relevance and patient benefit….

PULS changes its name to AQILION AB

Today the company Partners för Utvecklingsinvesteringar inom Life Science, P.U.L.S. AB is changing its name to AQILION AB. The name change marks a new phase in the development of the company, with…

Share this page

Subscribe

Read more about our Protection of your personal data.